Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Army
Colorcon
Dow
Julphar
Farmers Insurance
McKesson
Federal Trade Commission
QuintilesIMS
US Department of Justice

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,459,428

« Back to Dashboard

Summary for Patent: 7,459,428
Title:Method of regulating glucose metabolism, and reagents related thereto
Abstract:One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
Inventor(s): Bachovchin; William W. (Melrose, MA), Plaut; Andrew G. (Lexington, MA), Drucker; Daniel (Toronto, CA)
Assignee: Trustees of Tufts College (Medford, MA) New England Medical Center Hospitals, Inc. (Boston, MA) 1149336 Ontario, Inc. (Toronto, Ontario, CA)
Application Number:11/487,947
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;

Drugs Protected by US Patent 7,459,428

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-002 Feb 2, 2012 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-003 Feb 2, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-001 Feb 2, 2012 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN ➤ Subscribe
Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin TABLET;ORAL 206073-001 Jan 30, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN ➤ Subscribe
Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin TABLET;ORAL 206073-002 Jan 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN ➤ Subscribe
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-002 Mar 30, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-001 Mar 30, 2007 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme JANUVIA sitagliptin phosphate TABLET;ORAL 021995-001 Oct 16, 2006 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,459,428

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,803,357 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
8,513,190 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
7,829,530 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
8,318,669 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
6,890,898 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
7,078,381 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
7,157,429 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
9,044,424 Methods of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,459,428

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2017008092 ➤ Subscribe
Japan 2014144986 ➤ Subscribe
Japan 2014144985 ➤ Subscribe
Japan 2010248253 ➤ Subscribe
Japan 2010248252 ➤ Subscribe
Japan 2005041885 ➤ Subscribe
Japan 2002501889 ➤ Subscribe
Spain 2288807 ➤ Subscribe
European Patent Office 2823812 ➤ Subscribe
European Patent Office 2583675 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Dow
Mallinckrodt
Moodys
Farmers Insurance
Deloitte
Federal Trade Commission
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot